Results 161 to 170 of about 6,946 (216)
Fourth Nerve Palsy After Hair Replacement Surgery and Prolonged Vertical Position in a Patient With Mega-Cisterna-Magna: Report of a Case. [PDF]
CureusGonzález Martín-Moro J +4 more
europepmc +1 more source
The Benefits of Testosterone Treatment in Prostate Cancer. [PDF]
Dtsch Arztebl IntKoch CA, Chehade JM.
europepmc +1 more source
Paradoxical Nonscarring Alopecia Following Mesotherapy with Dutasteride: A Case Series.
Int J TrichologyChandrashekhar M +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs & Aging, 2003
Dutasteride, a potent inhibitor of type 1 and 2 5alpha-reductase, reduced dihydrotestosterone levels by >90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. A combined analysis of three placebo-controlled clinical studies conducted in patients with benign prostatic hyperplasia (BPH) found sustained improvements in ...
Hannah C, Evans, Karen L, Goa
+7 more sources
Dutasteride, a potent inhibitor of type 1 and 2 5alpha-reductase, reduced dihydrotestosterone levels by >90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. A combined analysis of three placebo-controlled clinical studies conducted in patients with benign prostatic hyperplasia (BPH) found sustained improvements in ...
Hannah C, Evans, Karen L, Goa
+7 more sources
Dutasteride and Prostate Cancer [PDF]
New England Journal of Medicine, 2010 Contains fulltext : 88812.pdf (Publisher’s version ) (Open Access)
Maarten C Bosland
exaly +8 more sources
The Cardiovascular Safety of Dutasteride
Journal of Urology, 2017Randomized controlled trials suggest an increased risk of heart failure with dutasteride, which inhibits both the type 1 and type 2 isoforms of 5α-reductase. In contrast, no such association has been suggested for finasteride, which selectively inhibits the type 2 isoform.
Sean C, Skeldon +6 more
openaire +2 more sources
Drugs & Aging, 2012
The 5α-reductase inhibitor dutasteride and the α(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater ...
openaire +2 more sources
The 5α-reductase inhibitor dutasteride and the α(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater ...
openaire +2 more sources
Dutasteride and Prostate Cancer Risk
Current Urology Reports, 2010In a previously published and heavily discussed paper [1], the type 2 5-α-reductase inhibitor (5ARI) finasteride was shown to reduce the risk of prostate cancer by a substantial 25% as compared to placebo in men at no known risk of developing prostate cancer.
openaire +2 more sources